8 recruiting, 7 completed, 4 not yet recruiting, 3 active not recruiting. 13 Phase 1, 11 Phase 2, 2 Phase 3, 1 Not applicable.
Follow Chengdu Zenitar Biomedical Technology Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets 75mg Flonoltinib, 100mg Flonoltinib - Drug Interaction Research | Phase 1 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 40 | 2026-10-30 | 2026-08-19 |
| Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants 19 mg /50 μCi of [¹⁴C] Purinostat Mesylate - MB | Phase 1 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 6 | 2026-09-28 | 2026-09-09 |
| Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China This group of participants take ZL-65 tablet, This group of participants take ZL-65 placebo tablet - Healthy Participants Study | Phase 1 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 108 | 2026-07-23 | 2026-08-11 |
| Mass Balance Study of [14C] Flonoltinib Maleate Flonoltinib 75mg - MB | Phase 1 | Completed | Chengdu Zenitar Biomedical Technology Co., Ltd | 6 | 2026-07-06 | 2026-08-13 |
| A Clinical Study of ZL-85FA Tablets ZL-85FA tablets - Advanced Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 51 | 2026-06-30 | 2026-01-15 |
| A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis Flonoltinib Maleate - MF | Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 64 | 2026-03-18 | 2026-08-13 |
| A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis Flonoltinib 75mg, Ruxolitinib Phosphate - MF | Phase 3 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-02-13 | 2026-08-13 |
| A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis The high-dose group of ZL-82 tablets, The low-dose group of ZL-82 tablets, The placebo group - Atopic Dermatitis | Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 111 | 2026-02-03 | 2026-02-04 |
| Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg - Polycythemia Vera (PV) | Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 60 | 2025-09-23 | 2026-08-14 |
| A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma Purinostat Mesylate for Injection, Selinexor Tablets - Recurrent and Refractory Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 390 | 2025-07-18 | 2025-09-19 |
| A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets flunotinib - Heathly Subjects | Phase 1 | Completed | Chengdu Zenitar Biomedical Technology Co., Ltd | 24 | 2024-08-04 | 2025-09-26 |
| A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors A0/B0 group Purinostat Mesylate 11.2mg/m2, A0/B0 group Purinostat Mesylate 15mg/m2, A group Purinostat Mesylate 6mg/m2 - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 132 | 2024-05-08 | 2025-04-10 |
| A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis Flonoltinib 50mg, Flonoltinib 100mg, Ruxolitinib - MF,PMF,PPV-MF,PET-MF | Phase 2 | Active not recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 75 | 2024-05-06 | 2026-08-12 |
| A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma 11.2 mg/m2 Purinostat Mesylate, 15 mg/m2 Purinostat Mesylate - Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | Active not recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 50 | 2024-04-14 | 2026-02-06 |
| Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2, Purinostat Mesylate 8.4 mg/m2 - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 144 | 2024-03-25 | 2025-04-02 |
| ZL-82 Double-blind Clinical Trial ZL-82, ZL-82 placebo - Healthy Person | Phase 1 | Completed | Chengdu Zenitar Biomedical Technology Co., Ltd | 41 | 2024-03-19 | 2025-10-01 |
| A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects Flonoltinib Maleate Tablets, Flonoltinib Maleate Tablets placebo - Heathly Subjects | Phase 1 | Completed | Chengdu Zenitar Biomedical Technology Co., Ltd | 40 | 2024-03-18 | 2025-09-23 |
| Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection SOC - COVID-19 | Not applicable | Terminated | Chengdu Zenitar Biomedical Technology Co., Ltd | 13 | 2023-05-23 | 2026-08-14 |
| Phase I Clinical Study of ZL-82 Tablets ZL-82 12.5mg, ZL-82 25mg, ZL-82 50mg - Rheumatoid Arthritis (RA), Inflammatory Bowel Disease - IBD1 | Phase 1 | Completed | Chengdu Zenitar Biomedical Technology Co., Ltd | 69 | 2023-04-09 | 2025-04-03 |
Showing 20 of 23. Sign in to see all of them.
Recurrence (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Anemia (1) · Arthritis, Rheumatoid (1) · COVID-19 (1) · Crohn Disease (1) · Dermatitis, Atopic (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1)
ruxolitinib (2) · Injections (1) · selinexor (1)
China (22)
Ting Niu, Doctor (6) · Yongsheng Wang, Doctor (3) · Weili Zhao, Doctor (2) · Xiaolan Yong, bachelor (2) · Chen Lijuan, doctor (1) · Herui Yao, Doctor (1) · Lei Zhang, Doctor (1) · Miao Jia, Doctor (1) · Niu Ting (1) · Niu Ting, Doctor (1) · Wei Yang, Doctor (1) · Xiao Zhijian (1) · Xiao Zhijian, Doctor (1) · Yong Xiaolan, Doctor (1) · Zhijian Xiao, Doctor (1)